Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PROBLEM: HEART DISEASE IS A KILLER No.1
Nearly 1 in 3 deaths in the USA are caused by heart
disease and stroke. Of the approximately 1.5 million
people suffering heart attacks annually in the U.S., more
than 250,000 will die within one hour of their incident.
Nearly 1/3 of the ~ 600,000 annual cardiovascular
disease deaths in the U.S. could be prevented through
changes in lifestyle habits. Unfortunately, for up to 50%
of these individuals, the FIRST SYMPTOM of coronary
artery disease is sudden cardiac death, or a heart attack.
SIMPLE INTRODUCING TO LXGTF
Lexington BioSciences introduces HeartSentry, a simple,
yet revolutionary technology for personalized measurement
and monitoring of vascular health to detect the potential
for cardiovascular disease at its earliest stages. The
device measures the function of the endothelium, the cells
that line all arteries and are critical to the prevention of
atherosclerosis, heart attacks and stroke.
The market cake is impressive so whoever want earn he will but he will invest also in a life saving product and this is even more worthy in my oppinion.
We have the enemy no 1 of a human life and LXGTF is a solution, that's awesome!
If anyone NEW here, this VIDEO is for you to understand fast!
Good idea italian, good morning!
Good morning everybody!
See you tmrw guys, have a great day!
Lets see tmrw the breaktrough and a new level
We are blessed ...exactly
Well said Door2door lol
How to make the glorytrain faster.
This is a rare situation where the funders are also technician and management
It looks to ne as well, green NYE lol
Good question...
And is moving higher!
Update more then welcome
This will be a green week where we can expect that breakout finaly!
.443 green +3.41
Wow just in the face of haters.
Wow great vision!
Nice article here!
LXGTF is something running great even before the FDA aproval which is a formality coming in 2T18
LXGTF in final green week probably in bteaktrough. Watchlist priorities...
LXGTF runnung green for breaktrough. Check what is about. License coming in 2018.
We have the priviledge to have the right information and be in the right place
Huh the team is extraordinary
Who cannot see it is really blind
That's LXGTF mitologicaly explained!
Yes what to do, moving slow but firm
It will be an explosion
the volume is pretty low
Power Hour coming, green +2,7% still .44
LXGTF announced receipt of the first HeartSentry human-use units from its manufacturer. http://techstockinsider.com/lexington-biosciences-lxgtf-receives-heartsentry-trial-units/
INDUSTRY WORTH BILLIONS HAVE YOU SOW IT
http://techstockinsider.com/the-wearable-tech-thats-disrupting-an-industry-worth-billions/
LXGTF Values
Excellence. Create a challenging and dynamic environment with excellence as an achievable goal in all we do.
Progress. Our work is focused on improving the lives of others. We believe the tools to achieve a healthy society must improve and we intend to be a positive part of this ongoing evolution.
Innovate. Consistently deliver exceptional products, identify clearly unmet needs and solve them, and always seek the potential for ever better results.
Trust. Engender trust by always performing in an ethical and professional manner.
Respect. Treat our stakeholders, investors, vendors, suppliers and future customers as we would like to be treated ourselves.
Mission Statement
Lexington Biosciences seeks to create and promote a suite of meaningful data centered cardiovascular monitoring technologies to provide patients relevant metrics so that they can lead longer and healthier lives.
LXGTF is potential 50 Billion Dollar Industry Penny Stock to Watch!
Read More here:
https://t.co/4nL5f2LtnQ
LXGTF is potential 50 Billion Dollar Industry Penny Stock to Watch!
Read More here:
https://t.co/4nL5f2LtnQ
About Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit:
https://lexingtonbiosciences.com/
Eric Willis
CEO & Director